| Original language | English |
|---|---|
| Pages (from-to) | E199-E203 |
| Journal | American Journal of Hematology |
| Volume | 95 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 1 2020 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: American Journal of Hematology, Vol. 95, No. 8, 01.08.2020, p. E199-E203.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Management of CLL patients early in the COVID-19 pandemic
T2 - An international survey of CLL experts
AU - Koffman, Brian
AU - Mato, Anthony
AU - Byrd, John C.
AU - Danilov, Alexey
AU - Hedrick, Brad
AU - Ujjani, Chaitra
AU - Roeker, Lindsey
AU - Stephens, Deborah M.
AU - Davids, Matthew S.
AU - Pagel, John M.
AU - Shadman, Mazyar
N1 - Funding Information: Brian Koffman: Consultation: Abbvie, Astra Zeneca, Janssen, Novartis, Verastem. Speakers Bureau: Bristol Myers Squibb, Celgene, TG Therapeutics. Anthony Mato holds a consultancy role for TG Therapeutics (in addition DSMB), Abbvie, Pharmacyclics, Johnson & Johnson, Regeneron, Astra Zeneca, Genentech, LOXO, and Celgene. And, he has received research funding from TG Therapeutics, Abbvie, Pharmacyclics, Johnson & Johnson, Regeneron, Genentech, LOXO, Portola, DTRM, and Acerta. John C. Byrd hasclinical trial research funding from Acerta, Pharmacyclics, and Celgene. He Consults with Astra Zeneca, Acerta, Janssen Oncology, Pharmacyclics, and Verastem. Dr. Byrd is supported by the National Cancer Institute (R35 CA198183, JCB). Alexey Danilov has received research funding from Astra Zeneca, Gilead Sciences, Genentech, Aptose Biosciences, MEI Pharma, Takeda Oncology, Bayer Oncology, Verastem Oncology and Bristol-Meyers-Squibb; honoraria from Astra Zeneca, Celgene, Curis, Genentech, Gilead Sciences, Janssen Oncology, Pharmacyclics, Seattle Genetics, TG Therapeutics and Verastem Oncology. He is a Leukemia and Lymphoma Society Scholar in Clinical Research. Brad Hedrick: none. Chaitra Ujjani: Consulting for Gilead/Kite, Verastem, Atara, Genentech Research: Abbvie, pharmacyclics, AstraZeneca. Lindsey Roeker has research funding from American Society of Hematology, minority ownership interest in Abbvie and Abbott Laboratories. Deborah Stephens receives consulting fees from Pharmacyclics and Jannsen. She receives research funding from Acerta, Gilead, Karyopharm, Juno, Verastem, and honoraria from Genentech. Matthew Davidsreceives personal fees from AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, Beigene, Celgene, Genentech, Gilead Sciences, Janssen, MEI Pharma, Pharmacyclics, Research to Practice, Syros Pharmaceuticals, TG Therapeutics, and Verastem. He receives institutional research funding from Astra-Zeneca, Ascentage Pharma, Genentech, MEI Pharma, Pharmacyclics, Surface Oncology, TG Therapeutics and Verastem, outside the submitted work. John Pagel holds a consultancy role for TG Therapeutics, Pharmacyclics, Astra Zeneca, Lily, and Gilead. Mazyar Shadman consults with and is on the advisory boards of Abbvie, Genentech, Astra Zeneca, Sound Biologics, Pharmacyclics, Verastem, ADC Therapeutics, Cellectar, Bristol Myers Squibb and Atara Biotherapeutics. Research Funding: Mustang Bio, Celgene, Bristol Myers Squibb, Pharmacyclics, Gilead, Genentech, Abbvie, TG Therapeutics, Beigene, Astra Zeneca, Sunesis, Acerta Pharma, Beigene and Merck. This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.
PY - 2020/8/1
Y1 - 2020/8/1
UR - https://www.scopus.com/pages/publications/85084482195
U2 - 10.1002/ajh.25851
DO - 10.1002/ajh.25851
M3 - Letter
C2 - 32356356
AN - SCOPUS:85084482195
SN - 0361-8609
VL - 95
SP - E199-E203
JO - American Journal of Hematology
JF - American Journal of Hematology
IS - 8
ER -